GlobeNewswire

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

Share

●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment


Basel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.

“Today's approval reflects our commitment to continued innovation with Xolair to address the critical needs of people living with allergic and inflammatory conditions,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Appropriate patients will now have the flexibility to administer Xolair from home, which is particularly important for those who are considered high-risk during the COVID-19 pandemic.”

Before starting self-injection with Xolair prefilled syringe, the patient must have no prior history of anaphylaxis and be closely observed by a healthcare provider for at least three injections with no hypersensitivity (allergic reactions). After Xolair therapy has been initiated and safely established in a healthcare setting, a healthcare provider may determine whether self-injection with Xolair prefilled syringe by the patient or a caregiver is appropriate. The healthcare provider must train the patient or caregiver on the correct subcutaneous injection technique, how to recognize the signs and symptoms of anaphylaxis and how to treat anaphylaxis appropriately, before the first self-injection outside a healthcare setting.

“Expanding treatment options for personalised care and self-management is always welcome news for the patient community,” said Kenneth Mendez, CEO and President, Asthma and Allergy Foundation of America. “The possibility of administering FDA-approved treatment outside of the healthcare provider’s office, but still guided by that healthcare provider, may reduce barriers to care for patients and their caregivers.”

Approximately 460,000 patients have been treated in the U.S. with Xolair since its initial approval in 2003.2 The use of Xolair across allergic asthma, CIU and nasal polyps is based on its well-established efficacy and safety profile and supported by a robust clinical development program, including 10 Phase III studies.1

In the U.S., Genentech, a member of the Roche group, and Novartis Pharmaceuticals Corporation work together to develop and co-promote Xolair.

About Xolair
Xolair is the only approved antibody designed to target and block immunoglobulin E (IgE). By reducing free IgE, down-regulating high-affinity IgE receptors and limiting mast cell degranulation, Xolair minimizes the release of mediators throughout the allergic inflammatory cascade.

About Roche in Immunology
The Roche Group’s immunology medicines include: Actemra®/RoActemra® (tocilizumab) for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and giant cell arteritis (GCA) and for the treatment of severe or life-threatening chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome (CRS); Rituxan®/MabThera® (rituximab) for rheumatoid arthritis granulomatosis with polyangiitis and microscopic polyangiitis and for pemphigus vulgaris (PV); Xolair® (omalizumab) for allergic asthma and chronic idiopathic urticaria (CIU); Pulmozyme® (dornase alfa) for cystic fibrosis; and Esbriet® (pirfenidone) for idiopathic pulmonary fibrosis (IPF). Roche has more than 15 investigational medicines in clinical development for immunological diseases that include asthma, autoimmune diseases, rheumatoid arthritis, ulcerative colitis and Crohn's disease.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Xolair® Full Prescribing Information. Genentech, Inc.; November 2020. 
[2] Data on file. Genentech, Inc.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Patrick Barth
Phone: +41 61 688 44 86
Dr. Daniel Grotzky
Phone: +41 61 688 31 10

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Meetz
Phone: +41 61 687 43 05
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67


Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Marimekko and UNIQLO announce a new spearhead collaboration collection celebrating summer6.5.2021 09:00:00 CEST | Press release

Marimekko Corporation, Press release, 6 May 2021 at 10.00 a.m. Marimekko and UNIQLO, a Japanese global apparel retailer, are happy to announce a new limited edition capsule collection for Spring/Summer 2021. The UNIQLO x Marimekko collection, celebrating midsummer traditions, represents one of the spearhead collaborations for UNIQLO in 2021, and will be available from 19 May onward. The new capsule is inspired by the joy and optimism of Nordic midsummer. The collection features dresses and other timeless wardrobe staples as well as accessories for women and children in iconic, summery Marimekko patterns by Fujiwo Ishimoto, Maija Isola, Maija Louekari and Annika Rimala. Following the success of the earlier limited edition UNIQLO x Marimekko collaborations, the capsule combines Marimekko’s colorful and cheerful prints with UNIQLO’s high-quality, functional and accessible LifeWear made for all. The collection will be available in all UNIQLO markets except Japan, Indonesia, and India. Most

Van Lanschot Kempen completes share buy-back programme6.5.2021 08:30:00 CEST | Press release

Amsterdam/’s-Hertogenbosch, the Netherlands, 6 May 2020 Van Lanschot Kempen today announced that it has successfully completed its share buy-back programme. In the last period, between 4 May 2021 and 5 May 2021, Van Lanschot Kempen repurchased 17,700 of its own shares (depositary receipts for Class A ordinary shares) at an average price of €24.21 per share for a total amount of €428,567. A total of 400,000 shares have been repurchased under the programme at an average price of €23.63 per share, representing a total amount of €9,451,734. The programme was announced on 25 February 2021. The repurchased shares will be used to cover the depositary receipts to be allocated to employees under existing remuneration policies and share plans. More information, including a detailed overview of all repurchase transactions under this programme, is available at www.vanlanschotkempen.com/sharebuyback. Media Relations: +31 20 354 45 85; mediarelations@vanlanschotkempen.com Investor Relations: +31 20

HOYLU AB: NUMBER OF USERS INCREASED 9% IN APRIL6.5.2021 08:30:00 CEST | Press release

Stockholm, Sweden, May 6, 2021 – Hoylu, a leader in visual collaboration solutions for distributed teams, today announced user numbers and Annual Recurring Revenue (“ARR)” as of the end of April 2021. The report for April 2021 is attached to this press release and is available on Hoylu's web site: (https://www.hoylu.com/investor-relations/financial-reports/). For more information, please contact: Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.com Karl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.com About Hoylu Hoylu’s mission is to empower distributed teams to collaborate easily and seamlessly while always staying in sync. Hoylu’s Connected Workspaces™ helps enterprises as well as small and medium companies run projects, programs, and initiatives across time zones and continents with the same level of engagement and clarity as if everyone were working in the same room. For more information: www.hoylu.com Try Hoylu for free: https://www.hoylu.com/signup/ Ticker

HOYLU AB: ANTAL ANVÄNDARE ÖKADE MED 9% I APRIL6.5.2021 08:30:00 CEST | Pressemelding

Stockholm, Sverige, 6 maj 2021 – Hoylu, ledande inom visuella samarbetslösningar för distribuerade team, presenterade idag antal användare och Årliga återkommande intäkter (ARR) från och med slutet av april 2021. Rapporten för april 2021 bifogas detta pressmeddelande och finns tillgänglig på bolagets hemsida: (https://www.hoylu.com/investor-relations/financial-reports/). För mer information kontakta: Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.com Karl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.com Om Hoylu Hoylus uppdrag är att ge distribuerade team möjlighet att samarbeta enkelt och sömlöst samtidigt som de alltid håller sig synkroniserade. Hoylus Connected Workspaces™ hjälper företag såväl stora som små att driva projekt, program och initiativ över olika tidszoner och kontinenter med samma engagemang och tydlighet som om alla arbetade i samma rum. För mer information: www.hoylu.com Testa Hoylu gratis: https://www.hoylu.com/signup/ Kortnamn: Hoylu Markna

Statkraft AS: Result for the first quarter6.5.2021 08:00:00 CEST | Press release

Record-high operating result (Oslo, 6 May 2021) Higher power prices and increasedgeneration resulted in a record-high underlying operating result. Statkraft continued to deliver on its strategy and initiated new renewable projects in the quarter. The underlying EBIT was NOK 7.2 billion in the quarter, an increase of NOK 3.1 billion from the first quarter last year. “The underlying operating result was the best ever achieved in a single quarter, following higher Nordic power prices and successful energy management”, says CEO Christian Rynning-Tønnesen. The average Nordic system price was 42.3 EUR/MWh, an increase of 26.9 EUR compared with the low price in the first quarter of 2020. Total power generation increased by 16 per cent to 20.6 TWh. A strengthening of NOK against EUR had a positive effect on net financial items, which ended at NOK 1.5 billion. Net profit was NOK 4.8 billion, an increase of NOK 6.7 billion compared with the result in the first quarter last year. Cash flow from o

Bayport Management Limited Appointment of Board Chairperson6.5.2021 08:00:00 CEST | Press release

APPOINTMENT OF BOARD CHAIRPERSON The Board of Bayport Management Ltd (“BML” or the “Company”) wishes to apprise its shareholders and the general public that Nicholas Haag has been appointed as the Chairperson of the Board of the Company, from April 2021. Mr. Haag has served as an Independent Non-Executive Director of the Company since 2016. Mr. Haag has had a 30- year career in the finance industry with various institutions including Barclays, ABN AMRO and the Royal Bank of Scotland. Most recently, Mr. Haag was a member of the Boards of TBC Bank Group PLC and Citadele Bank Group. Mr. Haag holds a First-Class Honours Degree from the University of Oxford. By order of the Board 6 May 2021 For additional information, please contact: David Rajak Investor Relations Executive (investor@bayportfinance.com / +27 11 236 7300) This information is information that Bayport Management Ltd is obliged to make public in accordance with the EU Market Abuse Regulation. The information was submitted for p

Statkraft AS: Resultat for første kvartal6.5.2021 08:00:00 CEST | Pressemelding

Rekordhøyt driftsresultat (Oslo, 6.mai 2021) Høyere kraftpriser og -produksjon ga Statkraft et rekordhøyt underliggende driftsresultat. Statkraft fortsetter å levere på strategien, og initierte flere nye fornybarprosjekter i kvartalet. Underliggende driftsresultat var 7,2 milliarder kroner i kvartalet, en forbedring på 3,1 milliarder kroner sammenlignet med samme kvartal i fjor. - Det underliggende driftsresultatet er det beste i et enkeltstående kvartal noensinne og er et resultat av høyere nordiske kraftpriser og vellykket energidisponering, sier konsernsjef Christian Rynning-Tønnesen. Den gjennomsnittlige nordiske systemprisen var 42,3 EUR/MWh. Det er en økning på 26,9 EUR/MWh sammenlignet med de lave prisene i første kvartal 2020. Samlet kraftproduksjon var 20,6 TWh, en økning på 16 prosent. En styrking av norske kroner mot euro hadde en positiv effekt på netto finansposter som endte på 1,5 milliarder kroner. Resultat etter skatt endte på 4,8 milliarder kroner, en forbedring på 6,7